Do pharmaceutical companies prioritise profit over safety?

1) What kind of claim is this?

This is a motive and harm claim about industry behaviour.

2) What context is assumed or missing?

Evidence of specific actions and regulatory responses is not described.

3) What has to be true for this to work?

Profit incentives would need to override safety standards in practice.

4) When would this not hold?

The claim weakens if safety systems effectively constrain decisions.

5) What follows if we accept it?

Confidence in drug approval processes may decline.